Literature DB >> 18030569

Adenovirus expressing mutant p27kip1 enhanced apoptosis and inhibited the growth of xenografted human breast cancer.

Tsuyoshi Sasaki1, Yu Katayose, Kuniharu Yamamoto, Masamichi Mizuma, Satoru Shiraso, Shinichi Yabuuchi, Akira Oda, Toshiki Rikiyama, Masaya Oikawa, Toru Onogawa, Masanori Suzuki, Choon-Taek Lee, Michiaki Unno.   

Abstract

PURPOSE: To evaluate the anti-tumor effects of a novel adenovirus expressing mutant p27(kip1) (Adp27-mt), which consists of a mutation of Thr-187/Pro-188 to Met-187/Ile-188.
METHODS: Using the human breast cancer cell lines, MDA-MB-231, ZR-75-1, and MCF-7, we tested Adp27-mt for cell cycle assay, growth inhibition assay, and TdT-mediated dUTP-biotin nick end labeling in a human breast cancer-grafted severe combined immunodeficiency (SCID) mouse model.
RESULTS: The mutant p27(kip1) induced stronger apoptosis in the breast cancer cell lines than adenovirus expressing wild-type p27(kip1) (Adp27-wt). Adp27-mt inhibits cell growth significantly; being about 5- and 3.5-fold stronger for IC50 than Adp27-wt in the breast cancer cell lines, MDA-MD-231 and ZR-75-1, respectively. In the human breast cancer-grafted SCID mouse model, Adp27-mt induced tumor regression and antitumor effects significantly better than Adp27-wt. Furthermore, Adp27-mt mainly caused G2/M arrest in the cell cycle progression, whereas Adp27-wt mediated a G1/S arrest 48 h after infection.
CONCLUSION: The mutant p27(kip1) protein induced apoptosis, and inhibited cell growth more efficiently with stronger anti-tumor effects than wild-type p27(kip1). Thus, the recombinant adenovirus expressing mutant p27(kip1) could be useful in gene therapy against breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18030569     DOI: 10.1007/s00595-007-3546-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  49 in total

1.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication.

Authors:  T Enoch; P Nurse
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

3.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

Authors:  Y Katayose; M Kim; A N Rakkar; Z Li; K H Cowan; P Seth
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

4.  p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis.

Authors:  V Masciullo; G Ferrandina; B Pucci; F Fanfani; S Lovergine; J Palazzo; G Zannoni; S Mancuso; G Scambia; A Giordano
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  Translational control of p27Kip1 accumulation during the cell cycle.

Authors:  L Hengst; S I Reed
Journal:  Science       Date:  1996-03-29       Impact factor: 47.728

6.  Manchester regional breast study--5 and 10 year results.

Authors:  J P Lythgoe; M K Palmer
Journal:  Br J Surg       Date:  1982-12       Impact factor: 6.939

7.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials.

Authors: 
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

8.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

9.  Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck.

Authors:  D K Frank; M J Frederick; T J Liu; G L Clayman
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

10.  Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas.

Authors:  A A Ferrando; M Balbín; A M Pendás; F Vizoso; G Velasco; C López-Otín
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.